HCPCS Level II code J9017 denotes a 1 mg unit of arsenic trioxide administered by injection, a chemotherapy agent used in specific hematologic malignancies. Nationally, accurate reporting of this HCPCS Level II code is important for tracking utilization, ensuring appropriate reimbursement for high-cost oncology drugs, and supporting quality measurement in cancer care delivery.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how this code is billed across typical infusion settings, common modifiers used with injectable chemotherapy, and payer coverage considerations. The publication outlines national benchmarks for unit pricing and utilization where available, summarizes relevant payer policy trends affecting injectable oncology drugs, and provides clinical context on the drug formulation and administration setting.

This summary is designed for clinicians, billing professionals, and policy analysts seeking a concise reference for HCPCS Level II code J9017, its clinical role, and the payer landscape relevant to arsenic trioxide injections.